Tafamidis
From Proteopedia
(Difference between revisions)
Line 3: | Line 3: | ||
<scene name='10/1006890/Overall/1'>Wild-type transthyretin in complex with tafamidis</scene> ([[3tct]]). | <scene name='10/1006890/Overall/1'>Wild-type transthyretin in complex with tafamidis</scene> ([[3tct]]). | ||
+ | |||
+ | <scene name='10/1006890/Binding_site/1'>Tafamidis binding site</scene>. | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> |
Revision as of 12:42, 6 November 2023
|
References
- ↑ "Vyndaqel- tafamidis meglumine capsule, liquid filled Vyndamax- tafamidis capsule, liquid filled". DailyMed. 30 August 2019. Retrieved 24 November 2019
- ↑ "Vyndaqel EPAR". European Medicines Agency. 16 October 2019. Retrieved 24 November 2019.
- ↑ "FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis". U.S. Food and Drug Administration. 14 September 2019. Archived from the original on 14 September 2019.